Enveric Biosciences, Inc. ENVB 深 滬
已收盤 01-09 16:00:00 美东时间
3.96
-0.120
-2.94%
華盛通- 最 高4.18
- 今 開4.18
- 成交量 2.23万股
- 最 低 3.9501
- 昨 收 4.08
- 總市值 236.41万
- 52周最高 63.00
- 市盈率 靜 --
- 換手率 3.74%
- 52周最低 3.50
- 委 比 86.27%
- 總股本 59.70万
- 歷史最高 2700000.00
- 量 比 0.71
- 振 幅 5.63%
- 歷史最低 3.50
- 每 手 1
- 風險率 12.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Enveric Biosciences Releases Updated Investor Presentation Materials
Enveric Biosciences ( ($ENVB) ) just unveiled an update. On or about January 9,...
01-10 06:49
Enveric Biosciences Announces Patent Issuance Of U.S. Patent No. 12,492,179 Entitled, "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives"
U.S. Patent expands the scope of patent protection and increases the number of molecules that Enveric has the potential to develop or license for the treatment of neuropsychiatric conditions.
2025-12-29 21:08
Enveric Biosciences Secures $3.1M Through Warrant Exercise
Enveric Biosciences ( ($ENVB) ) has issued an announcement. On December 11, 202...
2025-12-13 06:29
Enveric Biosciences Approves Key Stockholder Proposals
An announcement from Enveric Biosciences ( ($ENVB) ) is now available. On Decem...
2025-12-12 01:58
Enveric Biosciences shares are trading higher after the company received notice from the U.S. Patent and Trademark Office for a patent application covering its EVM301 series drug candidates.
Enveric Biosciences shares are trading higher after the company received notice...
2025-12-09 21:02
Enveric Biosciences Receives Notice of Allowance From U.S. Patent And Trademark Office For EVM401 Series Of Molecules For Mental Health Disorders Treatment
Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that
2025-11-26 21:03
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock rose 10.2% to $2.8 during Wedn...
2025-11-20 05:07
Enveric Biosciences GAAP EPS of -$10.81
Enveric Biosciences press release (ENVB): Q3 GAAP EPS of -$10.81. The net loss for the quarter included approximately $0.2 million in non-cash expenses related to stock-based compensation and other no...
2025-11-15 05:49
Enveric Biosciences Plans Reverse Stock Split
The latest update is out from Enveric Biosciences ( ($ENVB) ). Enveric Bioscien...
2025-10-24 05:05
Enveric Biosciences To Implement 1-For-12 Reverse Stock Split, Trading On Split-Adjusted Basis Starting October 28, 2025
Common Stock Will Begin Trading on a Split-Adjusted Basis on October 28, 2025Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small
2025-10-23 20:16
